Shopping Cart
Remove All
Your shopping cart is currently empty
Reozalimab (LY3434172) is a bispecific monoclonal antibody targeting PD-1/PD-L1, inhibiting the primary inhibitory receptor-ligand interaction within the PD-1 pathway. It exhibits antitumour efficacy and enhances T-cell activation in vitro.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $372 | - | In Stock | |
| 5 mg | $953 | - | In Stock | |
| 10 mg | $1,620 | 2-4 weeks | 2-4 weeks | |
| 25 mg | $2,380 | 2-4 weeks | 2-4 weeks | |
| 50 mg | $3,230 | 2-4 weeks | 2-4 weeks |
| Description | Reozalimab (LY3434172) is a bispecific monoclonal antibody targeting PD-1/PD-L1, inhibiting the primary inhibitory receptor-ligand interaction within the PD-1 pathway. It exhibits antitumour efficacy and enhances T-cell activation in vitro. |
| Synonyms | LY3434172, LY 3434172 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | PDCD1/PD-1/CD279 & PD-L1 |
| Molecular Weight | 144.16 kDa |
| Cas No. | 2445259-99-2 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.